Physician profile
Robert Bentley
NPI 1235509548
$21,032.86
in general payments reported to CMS, 2019-2025
19 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $727 · 2022: $999 · 2023: $958 · 2024: $840 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,592 · Consulting Fee: $3,742 · Food and Beverage: $3,612 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,330 · Education: $31.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,591.88 |
| Consulting Fee | $3,742.00 |
| Food and Beverage | $3,611.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,330.00 |
| Education | $31.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16,375.72 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $1,087.10 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $537.46 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $496.37 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $481.33 | 2021-2025 | Caplyta |
| Abbvie INC. | $340.82 | 2021-2025 | |
| Lundbeck LLC | $296.22 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $233.70 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $231.08 | 2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $230.77 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $211.76 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $164.34 | 2021-2025 | Ingrezza |
| Indivior INC. | $132.70 | 2021-2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $81.75 | 2021-2022 | |
| Uswm, LLC | $52.70 | 2023 | Zimhi, Lucemyra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $22.64 | 2024 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $22.58 | 2022 | |
| Abbott Laboratories | $18.49 | 2023 | Viewmate |
| Braeburn INC. | $15.33 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bentley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.